Proactive Investors
21 Oct 2026, 01:26 UTC · 1h ago
Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings
Impact · against what's priced in
Actinogen Medical (ACW) is approaching a binary valuation event with the expected mid-November release of XanaMIA trial results. The transition to database lock confirms the timeline for these results, which will determine the company's funding needs and viability for 2027.
- ACW+0.40
No priced-in read yet
- In context
The company has entered 'database lock' for the XanaMIA Alzheimer's trial, with results for the 247-patient cohort expected in mid-November.
Read from the article alone
